Pharmicell to Bring Stem Cell Therapy to European Market
Pharmicell Receives Manufacturing and Marketing Permit for Cell Therapy
Pharmicell received the official authorization for production of somatic cell therapeutics derived from adipose tissue. The license allows to produce and to market adipose tissue derived stem cells in Europe. With this permit, Pharmicell can provide its cell product (Twelve Cell SolutionTM) for a wide range of plastic-aesthetic therapies such as wrinkle and skin treatments, breast augmentation, and breast reconstruction after breast cancer surgery and radiation. According to the company, Pharmicell is the first in Europe to provide GMP-certified fat cell products for clinical uses. Pharmicell has completed LOIs with Clinica Vita and Charité to introduce its products. The fat cell service will be available to German customers immediately.
Pharmicell’s Twelve Cell SolutionTM is produced from patient’s own fat tissue - derived cells, a composition consisting of stem cells, fat cells and other regenerating cell types, and the fat tissue is processed under GMP conditions to isolate the cells, which will then be reapplied to the patient. The fat tissue can be collected from normal liposuction procedure or from biopsies. The option for storage of the cells for later use will be available by 2009.
Other news from the department research and development
